Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression

Share :
Published: 12 Jun 2015
Views: 1950
Rating:
Save
Dr Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece

Dr Meletios Dimopoulos talks to ecancertv at EHA 2015 about the results of ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone and is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read the news article for more.